AcelRx: DSUVIA efficacy and safety data to be presented at ASA
AcelRx Pharmaceuticals announced a poster presentation at the American Society of Anesthesiologists in San Francisco highlighting sublingual sufentanil. The poster presentation will include efficacy and integrated safety results of sufentanil sublingual tablets across surgery types. Included in this presentation are results from two randomized and placebo-controlled studies in post-operative patients following bunionectomy and abdominal surgery. Two studies were open-label and single-arm intended to evaluate sufentanil sublingual tablet 30 mcg in the emergency department and in older, post-operative patients, many with comorbidities. Statistically significant SPID12 differences were observed in favor of DSUVIA compared to placebo. Nausea was the most commonly reported AE across all surgery subgroups. The data will be presented at the American Society of Anesthesiologists ANESTHESIOLOGY 2018 Annual Meeting, October 13-17 in San Francisco, California.